Drug intelligence / Profile preview

SHR-4597

Development stage: Phase 2
Lead developer: Hengrui Pharmaceutical
Modality: Small Molecules
Administration: Inhalation, Oral

Overview

SHR-4597 is an investigational small molecule drug being developed by Guangdong Hengrui Pharmaceutical for the maintenance treatment of asthma. It is administered via inhalation and possibly oral routes, though clinical trials are focused on the inhaled formulation. The precise mechanism of action has not been disclosed or defined publicly. As of April 2024, SHR-4597 is in Phase I clinical trials to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics in both healthy subjects and patients with asthma[1][2][3][4].

Other names: SHR 4597SHR4597SHR-4597

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on SHR-4597.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SHR-4597.

Explore the full profile